Prediction of High Ovarian Response After Assisted Reproductive Techniques
HighART
High Response Predictive Parameters After Controlled Ovarian Stimulation in Women Undergoing Assisted Reproductive Techniques
1 other identifier
observational
300
1 country
1
Brief Summary
Polycystic ovarian syndrome (PCOS) patients have an increased risk of ovarian hyperstimulation syndrome (OHSS) after assisted reproduction techniques (ART). In addition, these women have a high risk of develop further metabolic disorders. Rotterdam criteria defined by the European Society of Human Reproduction and Endocrinology (ESHRE) are used for the diagnosis of PCOS. The aim of this study is both to determine the prevalence of PCOS in infertile patients who require ART in our Center and to evaluate the usefulness of each specific diagnosis criterium within Rotterdam criteria of PCOS as predictor of risk of OHSS. It also seeks to establish a cohort of patients identified according to specific Rotterdam criteria of PCOS to assess the incidence of long term complications.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2013
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2013
CompletedFirst Submitted
Initial submission to the registry
March 21, 2014
CompletedFirst Posted
Study publicly available on registry
February 9, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2015
CompletedFebruary 9, 2015
January 1, 2015
1.7 years
March 21, 2014
February 3, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Sensitivity, specificity, negative and positive predictive values of each inclusion criteria (independently and combined) to predict OHSS and high ovarian response after ART
18 months
Secondary Outcomes (3)
Prevalence of metabolic syndrome in the cohort of included patients
After COH for ART
Incidence of metabolic syndrome in patients with at least one criterion of PCOS
15 years in average
Incidence of cardiiovascular events in patients with at least one criterion of PCOS
15 years in average
Study Arms (1)
Initial cohort
Patients at risk of developing OHSS according to the inclusion criteria
Eligibility Criteria
Patients with primary infertility at risk of developing ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation. This population was defined according to the presence of at least one Rotterdam criterion or the presence of an abnromal luteal phase, invesion of the FSH/LH ratio or an increased AMH level (see inclusion and exclusion criteria below)
You may qualify if:
- Patients with primary infertility undergoing ovarian stimulation for IVF/ICSI plus one of the following criteria:
- Ovulation dysfunction.
- Androgen excess: clinical and/or biochemical.
- Polycystic ovary by transvaginal ultrasound in early follicular phase.
- AMH\>35 pmol/l
- FSH/LH\<1
- P4 levels on the day of menstrual cycle \<10ng/ml and cycle duration \<26 days
- Patients who undergo a second cycle after a previous one in which they were considered high responders (the cycle was canceled due to high risk of OHSS or the patient underwent coasting)
You may not qualify if:
- Age \<18 or \>39 years
- FSH \>10
- Uterine fibroids requiring surgery
- Diagnosis of hyperprolactinemia , hypothyroidism, congenital adrenal hyperplasia, Cushing's syndrome, ovarian tumors, adrenal tumors or hypogonadotropic hypogonadism
- Intake of oral contraceptives three months prior to the completion of IVF
- Diagnosis of endometriosis (by ultrasound or surgical findings)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
La Fe University Hospital
Valencia, Valencia, 46026, Spain
Study Officials
- PRINCIPAL INVESTIGATOR
Vicente Montañana-Ramirez, MD, PhD
Instituto de Investigaciones Sanitarias La Fe
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 30 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 21, 2014
First Posted
February 9, 2015
Study Start
October 1, 2013
Primary Completion
July 1, 2015
Study Completion
December 1, 2015
Last Updated
February 9, 2015
Record last verified: 2015-01